Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have received a consensus rating of "Buy" from the eleven brokerages that are covering the company, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $58.20.

Several equities research analysts have recently commented on the stock. Robert W. Baird boosted their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a report on Thursday, February 27th. HC Wainwright boosted their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research note on Friday, February 28th.

Mirum Pharmaceuticals Trading Up 0.1 %

Mirum Pharmaceuticals stock traded up $0.05 during mid-day trading on Friday, hitting $39.48. The company's stock had a trading volume of 254,014 shares, compared to its average volume of 522,812. Mirum Pharmaceuticals has a one year low of $23.14 and a one year high of $54.23. The stock has a market cap of $1.95 billion, a PE ratio of -19.57 and a beta of 1.00. The company has a 50 day moving average of $44.76 and a 200-day moving average of $43.97. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $99.41 million during the quarter, compared to analysts' expectations of $96.64 million. On average, research analysts anticipate that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, COO Peter Radovich sold 3,177 shares of the firm's stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $47.92, for a total transaction of $152,241.84. Following the sale, the chief operating officer now directly owns 29,588 shares of the company's stock, valued at $1,417,856.96. This trade represents a 9.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Christopher Peetz sold 27,279 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $1,206,004.59. Following the transaction, the chief executive officer now owns 138,641 shares of the company's stock, valued at approximately $6,129,318.61. This represents a 16.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 116,473 shares of company stock valued at $5,249,134. 22.87% of the stock is owned by insiders.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC acquired a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at about $28,913,000. Raymond James Financial Inc. purchased a new position in Mirum Pharmaceuticals during the fourth quarter worth approximately $10,611,000. Nuveen Asset Management LLC boosted its position in Mirum Pharmaceuticals by 46.7% during the fourth quarter. Nuveen Asset Management LLC now owns 722,155 shares of the company's stock worth $29,861,000 after purchasing an additional 229,746 shares in the last quarter. D. E. Shaw & Co. Inc. acquired a new stake in Mirum Pharmaceuticals in the fourth quarter valued at approximately $6,507,000. Finally, Marshall Wace LLP increased its position in shares of Mirum Pharmaceuticals by 641.6% in the fourth quarter. Marshall Wace LLP now owns 175,913 shares of the company's stock valued at $7,274,000 after buying an additional 152,191 shares in the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.